Literature DB >> 12459354

Correlation of clinical and pathologic features with outcome in patients with ductal carcinoma in situ of the breast treated with breast-conserving surgery and radiotherapy.

Neesha Rodrigues1, Darryl Carter, Deborah Dillon, Nicole Parisot, Doo Ho Choi, Bruce G Haffty.   

Abstract

PURPOSE: Although breast-conserving surgery followed by radiotherapy (RT) has become a standard treatment option for patients with ductal carcinoma in situ of the breast, risk factors for ipsilateral breast tumor recurrence (IBTR) in these patients remain an active area of investigation. The purpose of this study was to evaluate the impact of clinical and pathologic features on long-term outcome in a cohort of DCIS patients treated with breast-conserving surgery plus RT. METHODS AND MATERIALS: Between 1973 and 1998, 230 patients with DCIS were treated with breast-conserving surgery plus RT at our institution. All patients were treated by local excision followed by RT to the breast to a total median tumor bed dose of 64 Gy. Adjuvant hormonal therapy was used in only 20 patients (9%). All available clinical, pathologic, and outcome data, including ipsilateral and contralateral events, were entered into a computerized database. The clinical and pathologic variables evaluated included detection method, mammographic appearance, age, family history, histologic subtype, presence of necrosis, nuclear grade, final margin status, and use of adjuvant hormonal therapy.
RESULTS: As of December 15, 2000, with a median follow-up of 8.2 years, 17 patients had developed a recurrence in the ipsilateral breast, resulting in a 5- and 10-year IBTR rate of 5% and 13%, respectively. Contralateral breast cancer developed in 8 patients, resulting in a 10-year contralateral recurrence rate of 5%. Patient age, family history, histologic subtype, margin status, and tumor grade were not significantly associated with recurrence on univariate analysis. A significantly higher rate of local relapse was observed in patients with the presence of necrosis. The 10-year relapse rate was 22% in 88 patients with necrosis compared with 7% in 142 patients without necrosis (p <0.01). In multivariate analysis, the presence of necrosis remained a significant predictor of local relapse. No breast relapses occurred among the 8 patients with positive margins, and three relapses developed among 21 patients with close margins. The rate of IBTR in those with close/positive margins did not differ from the rate in those with negative or unknown margins. It is also notable that none of the 20 patients treated with adjuvant tamoxifen had developed IBTR or a contralateral event to date, although the follow-up on this group was still too short to reach significance.
CONCLUSION: In this cohort of uniformly treated patients with a relatively long follow-up, the presence of necrosis was a significant predictor of local relapse. However, positive or close margin status was not a significant predictor of local relapse. Although none of the patients receiving tamoxifen had a recurrence in the ipsilateral or contralateral breast, longer follow-up is required to assess the effect of tamoxifen on these end points.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12459354     DOI: 10.1016/s0360-3016(02)03747-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

Review 1.  Network meta-analysis of margin threshold for women with ductal carcinoma in situ.

Authors:  Shi-Yi Wang; Haitao Chu; Tatyana Shamliyan; Hawre Jalal; Karen M Kuntz; Robert L Kane; Beth A Virnig
Journal:  J Natl Cancer Inst       Date:  2012-03-22       Impact factor: 13.506

2.  Ductal Carcinoma In Situ and Margins <2 mm: Contemporary Outcomes With Breast Conservation.

Authors:  Audree B Tadros; Benjamin D Smith; Yu Shen; Heather Lin; Savitri Krishnamurthy; Anthony Lucci; Carlos H Barcenas; Rosa F Hwang; Gaiane Rauch; Lumarie Santiago; Eric A Strom; Sarah M DeSnyder; Wei T Yang; Dalliah M Black; Constance T Albarracin; Mariana Chavez-MacGregor; Kelly K Hunt; Henry M Kuerer
Journal:  Ann Surg       Date:  2019-01       Impact factor: 12.969

Review 3.  Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ.

Authors:  Tatyana Shamliyan; Shi-Yi Wang; Beth A Virnig; Todd M Tuttle; Robert L Kane
Journal:  J Natl Cancer Inst Monogr       Date:  2010

Review 4.  The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis.

Authors:  M Luke Marinovich; Lamiae Azizi; Petra Macaskill; Les Irwig; Monica Morrow; Lawrence J Solin; Nehmat Houssami
Journal:  Ann Surg Oncol       Date:  2016-08-15       Impact factor: 5.344

Review 5.  Ductal Carcinoma In Situ of the Breast: Evaluating the Role of Radiation Therapy in the Management and Attempts to Identify Low-risk Patients.

Authors:  Chirag Shah; Frank A Vicini; Sameer Berry; Thomas B Julian; John Ben Wilkinson; Simona F Shaitelman; Atif Khan; Steven E Finkelstein; Neal Goldstein
Journal:  Am J Clin Oncol       Date:  2015-10       Impact factor: 2.339

6.  Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry.

Authors:  Ellen T Chang; Roger L Milne; Kelly-Anne Phillips; Jane C Figueiredo; Meera Sangaramoorthy; Theresa H M Keegan; Irene L Andrulis; John L Hopper; Pamela J Goodwin; Frances P O'Malley; Nayana Weerasooriya; Carmel Apicella; Melissa C Southey; Michael L Friedlander; Graham G Giles; Alice S Whittemore; Dee W West; Esther M John
Journal:  Breast Cancer Res Treat       Date:  2008-11-26       Impact factor: 4.872

Review 7.  Margins in breast cancer: How much is enough?

Authors:  Melissa Pilewskie; Monica Morrow
Journal:  Cancer       Date:  2018-01-16       Impact factor: 6.860

8.  Conservative treatment of breast ductal carcinoma in situ: results of an Italian multi-institutional retrospective study.

Authors:  Cristiana Vidali; Orazio Caffo; Cynthia Aristei; Filippo Bertoni; Alberto Bonetta; Marina Guenzi; Cinzia Iotti; Maria Cristina Leonardi; Salvatore Mussari; Stefano Neri; Nicoletta Pietta
Journal:  Radiat Oncol       Date:  2012-10-25       Impact factor: 3.481

9.  The Selection of Treatment Modality for Breast Ductal Carcinoma In Situ: Experience From a Single Institution.

Authors:  Kai-Yun You; Zhuo-Fei Bi; Yu-Jia Ma; Yong-Lin Mao; Wei-Liang Zou; Yi-Min Liu; He-Rui Yao
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.